IL-31 is considered a Th2-type cytokine, and nemolizumab demonstrated significant efficacy in AD in a phase III double-blind trial, with marked improvements in VAS, EASI, and DLQI scores at week 16 [52]. This evidence concerns the gene IL31 and Alzheimer disease.